Monacolin K affects lipid metabolism through SIRT1/AMPK pathway in HepG2 cells

Chia Hsin Huang, Shin Mau Shiu, Min Tze Wu, Wei Lu Chen, Shyang Guang Wang, Horng Mo Lee

研究成果: 雜誌貢獻文章

8 引文 (Scopus)

摘要

Monacolin K is the secondary metabolite isolated from Monascus spp. It is the natural form of lovastatin, which is clinically used to reduce the synthesis of cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. In the present study, monacolin K increased protein expression of SIRT1 and phosphorylation level of AMP-activated protein kinase (AMPK) in HepG2 cells. Through activation of SIRT1/AMPK pathway, monacolin K increased phosphorylation of acetyl CoA carboxylase and caused nuclear translocation of forkhead box O1. The western blotting results showed that monacolin K increased expression of adipose triglyceride lipase but decreased abundances of fatty acid synthase (FAS) and sterol regulatory element-binding protein 1 (SREBP1). Monacolin K also decreased the intracellular accumulation of lipids as demonstrated by Oil Red O staining. In addition, the immunostaining showed that monacolin K prevented the nuclear translocation of SREBP1, indicating the association with down-regulation of FAS. All the demonstrated effects of monacolin K were counteracted by nicotinamide or compound C, the inhibitors of SIRT1 or AMPK. In summary, monacolin K reduces the lipid content through SIRT1/AMPK pathway in HepG2 cells, which promotes catabolism and inhibits anabolism of lipid.
原文英語
頁(從 - 到)1541-1551
頁數11
期刊Archives of Pharmacal Research
36
發行號12
DOIs
出版狀態已發佈 - 十二月 2013

指紋

Lovastatin
AMP-Activated Protein Kinases
Hep G2 Cells
Lipid Metabolism
Sterol Regulatory Element Binding Protein 1
Fatty Acid Synthases
Phosphorylation
Lipids
Monascus
Acetyl-CoA Carboxylase
Niacinamide
Metabolites
Lipase
Oxidoreductases
Down-Regulation
Western Blotting
Chemical activation
Cholesterol
Association reactions
Staining and Labeling

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Organic Chemistry

引用此文

Monacolin K affects lipid metabolism through SIRT1/AMPK pathway in HepG2 cells. / Huang, Chia Hsin; Shiu, Shin Mau; Wu, Min Tze; Chen, Wei Lu; Wang, Shyang Guang; Lee, Horng Mo.

於: Archives of Pharmacal Research, 卷 36, 編號 12, 12.2013, p. 1541-1551.

研究成果: 雜誌貢獻文章

Huang, Chia Hsin ; Shiu, Shin Mau ; Wu, Min Tze ; Chen, Wei Lu ; Wang, Shyang Guang ; Lee, Horng Mo. / Monacolin K affects lipid metabolism through SIRT1/AMPK pathway in HepG2 cells. 於: Archives of Pharmacal Research. 2013 ; 卷 36, 編號 12. 頁 1541-1551.
@article{903a2cf3da1b4b528c8cdffec1172232,
title = "Monacolin K affects lipid metabolism through SIRT1/AMPK pathway in HepG2 cells",
abstract = "Monacolin K is the secondary metabolite isolated from Monascus spp. It is the natural form of lovastatin, which is clinically used to reduce the synthesis of cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. In the present study, monacolin K increased protein expression of SIRT1 and phosphorylation level of AMP-activated protein kinase (AMPK) in HepG2 cells. Through activation of SIRT1/AMPK pathway, monacolin K increased phosphorylation of acetyl CoA carboxylase and caused nuclear translocation of forkhead box O1. The western blotting results showed that monacolin K increased expression of adipose triglyceride lipase but decreased abundances of fatty acid synthase (FAS) and sterol regulatory element-binding protein 1 (SREBP1). Monacolin K also decreased the intracellular accumulation of lipids as demonstrated by Oil Red O staining. In addition, the immunostaining showed that monacolin K prevented the nuclear translocation of SREBP1, indicating the association with down-regulation of FAS. All the demonstrated effects of monacolin K were counteracted by nicotinamide or compound C, the inhibitors of SIRT1 or AMPK. In summary, monacolin K reduces the lipid content through SIRT1/AMPK pathway in HepG2 cells, which promotes catabolism and inhibits anabolism of lipid.",
keywords = "AMPK, FoxO1, Lipid, Monacolin K, SIRT1, Statin",
author = "Huang, {Chia Hsin} and Shiu, {Shin Mau} and Wu, {Min Tze} and Chen, {Wei Lu} and Wang, {Shyang Guang} and Lee, {Horng Mo}",
year = "2013",
month = "12",
doi = "10.1007/s12272-013-0150-2",
language = "English",
volume = "36",
pages = "1541--1551",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "12",

}

TY - JOUR

T1 - Monacolin K affects lipid metabolism through SIRT1/AMPK pathway in HepG2 cells

AU - Huang, Chia Hsin

AU - Shiu, Shin Mau

AU - Wu, Min Tze

AU - Chen, Wei Lu

AU - Wang, Shyang Guang

AU - Lee, Horng Mo

PY - 2013/12

Y1 - 2013/12

N2 - Monacolin K is the secondary metabolite isolated from Monascus spp. It is the natural form of lovastatin, which is clinically used to reduce the synthesis of cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. In the present study, monacolin K increased protein expression of SIRT1 and phosphorylation level of AMP-activated protein kinase (AMPK) in HepG2 cells. Through activation of SIRT1/AMPK pathway, monacolin K increased phosphorylation of acetyl CoA carboxylase and caused nuclear translocation of forkhead box O1. The western blotting results showed that monacolin K increased expression of adipose triglyceride lipase but decreased abundances of fatty acid synthase (FAS) and sterol regulatory element-binding protein 1 (SREBP1). Monacolin K also decreased the intracellular accumulation of lipids as demonstrated by Oil Red O staining. In addition, the immunostaining showed that monacolin K prevented the nuclear translocation of SREBP1, indicating the association with down-regulation of FAS. All the demonstrated effects of monacolin K were counteracted by nicotinamide or compound C, the inhibitors of SIRT1 or AMPK. In summary, monacolin K reduces the lipid content through SIRT1/AMPK pathway in HepG2 cells, which promotes catabolism and inhibits anabolism of lipid.

AB - Monacolin K is the secondary metabolite isolated from Monascus spp. It is the natural form of lovastatin, which is clinically used to reduce the synthesis of cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. In the present study, monacolin K increased protein expression of SIRT1 and phosphorylation level of AMP-activated protein kinase (AMPK) in HepG2 cells. Through activation of SIRT1/AMPK pathway, monacolin K increased phosphorylation of acetyl CoA carboxylase and caused nuclear translocation of forkhead box O1. The western blotting results showed that monacolin K increased expression of adipose triglyceride lipase but decreased abundances of fatty acid synthase (FAS) and sterol regulatory element-binding protein 1 (SREBP1). Monacolin K also decreased the intracellular accumulation of lipids as demonstrated by Oil Red O staining. In addition, the immunostaining showed that monacolin K prevented the nuclear translocation of SREBP1, indicating the association with down-regulation of FAS. All the demonstrated effects of monacolin K were counteracted by nicotinamide or compound C, the inhibitors of SIRT1 or AMPK. In summary, monacolin K reduces the lipid content through SIRT1/AMPK pathway in HepG2 cells, which promotes catabolism and inhibits anabolism of lipid.

KW - AMPK

KW - FoxO1

KW - Lipid

KW - Monacolin K

KW - SIRT1

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84890791190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890791190&partnerID=8YFLogxK

U2 - 10.1007/s12272-013-0150-2

DO - 10.1007/s12272-013-0150-2

M3 - Article

C2 - 23657807

AN - SCOPUS:84890791190

VL - 36

SP - 1541

EP - 1551

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 12

ER -